Epidemiology of hematological malignancies
Epidemiology of hematological malignancies
复制标题
DOI：
10.1093/annonc/mdl443
复制
发表时间：
2007-02-01
影响因子：
50.5
通讯作者：
Zucca, E.
中科院分区：
文献类型：
--
作者：
Rodriguez-Abreu, D.;Bordoni, A.;Zucca, E.
血液恶性肿瘤包括一系列异质性疾病，所有疾病均源自骨髓和淋巴系统细胞。主要分为三类：白血病、淋巴瘤和浆细胞肿瘤。总体而言，在西方国家，血液恶性肿瘤的总体发病率似乎在上升，但很难以一致和统一的方式描述其流行病学行为，特别是在欧洲。欧盟 (EU) 成员国数量有所增加，这种扩张扩大了欧盟范围，纳入了多种民族，这些民族在生活方式习惯、疾病风险以及癌症发病率和死亡率（总体或特定地点）方面存在较大程度的异质性。此外，欧洲没有独特的血液癌症报告系统或登记系统，因此很难估计患者的确切数量。此外，欧洲各登记处报告的发病率比较可能存在偏差，因为它们的人口可能主要是城市或农村，或者因为登记的方法和准确性存在差异。 2005 年欧洲诊断出患有血液恶性肿瘤的新患者人数估计为 230 000 名。这些白血病、霍奇金淋巴瘤、非霍奇金淋巴瘤 (NHL) 和骨髓瘤的新病例占欧洲诊断的所有新癌症患者的 8%，这些肿瘤的估计死亡人数占 2005 年癌症相关死亡人数的 7%。 表 1 和表 2 总结了欧洲和美国主要血液癌症的发病率。 白血病在全球范围内超过 250每年有000人被诊断患有白血病，占所有癌症的2.5%。估计2005年欧洲将诊断出75 700名新的白血病患者。所有年龄组都可能受到影响；白血病是最常见的儿科肿瘤（占 0-14 岁儿童癌症的 35%）。然而，大多数病例发生在老年人中。超过一半是65岁以后。在美国 SEER 登记处，从 1998 年到 2002 年，诊断出白血病的中位年龄为 67 岁。大约 11% 在 20 岁以下被诊断； 20 岁至 44 岁之间为 11%； 45 岁至 54 岁之间 10%； 14% 之间
Hematological malignancies comprise a collection of heterogeneous conditions, all originating from cells of the bone marrow and the lymphatic system. There are three major groups: leukemia, lymphoma, and plasma cell neoplasms. In general, in Western countries the overall incidence of hematological malignancies appears to be rising but it is very difficult to describe in a consistent and uniform way their epidemiological behavior, especially in Europe. The number of European Union (EU) Member States has increased and this expansion enlarged the Union to incorporate a diversity of peoples with a much larger degree of heterogeneity in lifestyle habits and disease risk, as well as in cancer incidence and mortality (either overall or site-specific). Moreover, there is not a unique European reporting system or registry for hematological cancers, so the estimation of the exact number of patients is difficult. In addition, the comparison of the incidences reported by various European registries may be biased because their populations can be predominantly either urban or rural, or because there are differences in the methodology and accuracy of registration. The number of new patients in Europe diagnosed with hematological malignancies in 2005 can be estimated in 230 000 patients. These new cases of leukemia, Hodgkin’s and non-Hodgkin’s lymphoma (NHL) and myeloma account for 8% of all the new cancer patients diagnosed in Europe and the estimated deaths from these tumors account for 7% of the cancer-related deaths in 2005. Incidence rates for the main hematological cancers in Europe and the United States are summarized in Tables 1 and 2. leukemiaWorldwide, over 250 000 people are diagnosed with leukemia each year, accounting for 2.5% of all cancers. An estimated 75 700 new patients of leukemia will be diagnosed in Europe in 2005. All age groups can be affected; leukemias are the most common pediatric tumor (35% of cancers in children aged 0–14 years). Most cases, however, occur in older adults; more than half after 65 years of age. In the United States SEER registries, from 1998 to 2002, the median age at diagnosis for leukemia was 67 years. Approximately 11% were diagnosed under age 20; 11% between 20 and 44; 10% between 45 and 54; 14% between